NEW YORK (GenomeWeb News) - Eli Lilly & Co. said today that it will provide free access to its drug discovery technology to potential collaborators who want to evaluate the therapeutic potential of their compounds.

Under the new program, called the Phenotypic Drug Discovery Initiative, or PD2, Lilly said it will provide free, confidential access to its drug discovery assays via a secure web portal in a move intended to provide "a more convenient point of entry for global external researchers into Lilly's drug discovery and development process."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.